Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Estudo de Patritumab Deruxtecan com outros agentes anticancerígenos em participantes com câncer de mama HER2 positivo que se espalhou e não pode ser removido cirurgicamente (MK-1022-009)

12 de novembro de 2026 atualizado por: Merck Sharp & Dohme LLC

HERTHENA-Breast-01: Um estudo de fase 1b/2, multicêntrico, aberto, de determinação de dose para avaliar a segurança e a atividade antitumoral de Patritumab Deruxtecan em participantes com câncer de mama localmente avançado irressecável HER2 positivo ou câncer de mama metastático

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:

  • About the safety and how well people tolerate of patritumab deruxtecan
  • How many people have the cancer respond (get smaller or go away) to treatment

Visão geral do estudo

Descrição detalhada

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Tipo de estudo

Intervencional

Inscrição (Estimado)

181

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Ontario
      • Kingston, Ontario, Canadá, K7L 2V7
        • Recrutamento
        • Kingston General Hospital ( Site 0061)
        • Contato:
          • Study Coordinator
          • Número de telefone: 6135336541
      • Toronto, Ontario, Canadá, M5G 2M9
        • Recrutamento
        • Princess Margaret Cancer Centre ( Site 0001)
        • Contato:
          • Study Coordinator
          • Número de telefone: 416-946-4501
    • Quebec
      • Montreal, Quebec, Canadá, H3T 1E2
        • Recrutamento
        • Jewish General Hospital ( Site 0003)
        • Contato:
          • Study Coordinator
          • Número de telefone: 514-340-8222
      • Montreal, Quebec, Canadá, H2X 3E4
        • Recrutamento
        • Centre Hospitalier de l'Université de Montréal ( Site 0004)
        • Contato:
          • Study Coordinator
          • Número de telefone: (514)890-8000 x20737
      • Seoul, Coréia do Sul, 03080
        • Recrutamento
        • Seoul National University Hospital ( Site 0030)
        • Contato:
          • Study Coordinator
          • Número de telefone: 82-2-2072-0850
      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center ( Site 0031)
        • Contato:
          • Study Coordinator
          • Número de telefone: +82-2-1688-7575
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • University of Colorado Anschutz Medical Campus ( Site 0057)
        • Contato:
          • Study Coordinator
          • Número de telefone: 720-848-1030
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Recrutamento
        • Dana-Farber Cancer Institute ( Site 0050)
        • Contato:
          • Study Coordinator
          • Número de telefone: 877-338-7425
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08901
        • Recrutamento
        • Rutgers Cancer Institute of New Jersey ( Site 0052)
        • Contato:
          • Study Coordinator
          • Número de telefone: 732-235-2465
    • South Carolina
      • Greenville, South Carolina, Estados Unidos, 29605
        • Recrutamento
        • Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
        • Contato:
          • Study Coordinator
          • Número de telefone: 864-455-3600
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Recrutamento
        • Inova Schar Cancer Institute ( Site 0051)
        • Contato:
          • Study Coordinator
          • Número de telefone: 571-472-4724
      • Haifa, Israel, 3109601
        • Recrutamento
        • Rambam Health Care Campus ( Site 0011)
        • Contato:
          • Study Coordinator
          • Número de telefone: 04-7776234
      • Petah Tikva, Israel, 4941492
        • Recrutamento
        • Rabin Medical Center ( Site 0012)
        • Contato:
          • Study Coordinator
          • Número de telefone: +972-505533121
      • Ramat Gan, Israel, 5265601
        • Recrutamento
        • Sheba Medical Center ( Site 0010)
        • Contato:
          • Study Coordinator
          • Número de telefone: 03-5304498
    • Aichi-ken
      • Nagoya, Aichi-ken, Japão, 467-8602
        • Recrutamento
        • Nagoya City University Hospital ( Site 0020)
        • Contato:
          • Study Coordinator
          • Número de telefone: +81-52-851-5511
    • Camden
      • London, Camden, Reino Unido, NW1 2PG
        • Recrutamento
        • University College London Hospital ( Site 0041)
        • Contato:
          • Study Coordinator
          • Número de telefone: +442034472930
    • Glasgow City
      • Glasgow, Glasgow City, Reino Unido, G12 0YN
        • Recrutamento
        • The Beatson West of Scotland Cancer Centre ( Site 0043)
        • Contato:
          • Study Coordinator
          • Número de telefone: +441413017000
    • London, City of
      • London, London, City of, Reino Unido, EC1A 7BE
        • Recrutamento
        • St Bartholomew s Hospital ( Site 0040)
        • Contato:
          • Study Coordinator
          • Número de telefone: +442073777000

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
  • Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
  • Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
  • Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention

Part 1 Arm 1:

  • Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
  • Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment

Part 1 Arm 2:

-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting

Part 1 Arm 3:

-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.

Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Uncontrolled or significant cardiovascular disease
  • Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
  • Has clinically severe respiratory compromise
  • Has any history of or evidence of any current leptomeningeal disease
  • Has clinically significant corneal disease
  • Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
  • HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Part 1: Evidence of spinal cord compression or brain metastases
  • Part 2: Evidence of spinal cord compression or brain/CNS metastases.
  • Has an active infection requiring systemic therapy
  • Concurrent active HBV and HCV infection
  • Has had major surgical procedure (excluding placement of vascular access) less than 28 days

Part1: Arm 3 ONLY

- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part 1: Patritumab deruxtecan plus trastuzumab

Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Outros nomes:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Outros nomes:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®
Experimental: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Outros nomes:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Outros nomes:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

Experimental: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib

Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Outros nomes:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Outros nomes:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Tucatinib administered as oral tablets

Experimental: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab

Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision.

Patritumab deruxtecan administered via IV infusion

Outros nomes:
  • U3-1402
  • HER3-DXd
  • MK-1022

Trastuzumab administered via IV infusion

Outros nomes:
  • Herceptin®

Trastuzumab biosimilar administered via IV infusion

Outros nomes:
  • Trazimera®
  • Kanjinti®
  • Ogivri®
  • Herzuma®
  • Ontruzant®
  • Hercessi®

Pertuzumab administered via IV infusion

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Prazo: Up to 21 days

DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Prazo: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Prazo: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented.

Up to approximately 12 months
Part 2: Objective Response Rate (ORR)
Prazo: Up to approximately 36 months

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented.

Up to approximately 36 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA.

At designated time points (up to ~13 months)
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Prazo: At designated time points (up to ~13 months)

Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload.

At designated time points (up to ~13 months)
Part 2: Duration of Response (DOR)
Prazo: Up to approximately 36 months

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Progression Free Survival (PFS)
Prazo: Up to approximately 36 months

PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented.

Up to approximately 36 months
Part 2: Number of Participants with One or More AEs
Prazo: Up to approximately 36 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 36 months
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Prazo: Up to approximately 12 months

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented.

Up to approximately 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Colaboradores

Investigadores

  • Diretor de estudo: Medical Director, Merck Sharp & Dohme LLC

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

26 de fevereiro de 2025

Conclusão Primária (Estimado)

2 de agosto de 2032

Conclusão do estudo (Estimado)

2 de agosto de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

11 de novembro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de novembro de 2024

Primeira postagem (Real)

13 de novembro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

12 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 1022-009
  • MK-1022-009 (Outro identificador: MSD)
  • jRCT2041250022 (Identificador de registro: Japan Registry of Clinical Trials (jRCT))
  • 2026-528266-19 (Identificador de registro: EU CT)
  • U1111-1346-4321 (Identificador de registro: UTN)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever